cept Therapeutics rporated(US:CORT) Globenewswire·2026-02-26 13:34Core Viewpoint - A securities fraud class action lawsuit has been initiated against Corcept Therapeutics Incorporated, with a deadline for potential lead plaintiffs to file papers by April 21, 2026 [1][3]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Northern District of California on behalf of investors who purchased or acquired Corcept common stock between October 31, 2024, and December 30, 2025, alleging violations of the Securities Exchange Act of 1934 [4]. - The allegations include misrepresentations made by the defendants regarding the adequacy of clinical evidence supporting the New Drug Application for relacorilant, Corcept's lead product candidate for multiple indications, including treatment for hypercortisolism [5]. Group 2: Investor Actions - Investors who wish to participate in the class action can contact the Investor Relations Manager for more information and to discuss their legal rights and options [2][8]. - All representation in the lawsuit is on a contingency fee basis, meaning shareholders will not incur any fees or expenses unless there is a recovery [3].